HFM
IBRX icon

Hartford Financial Management’s ImmunityBio IBRX Stock Holding History

Hartford Financial Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Sell
11,498
-1,500
-12% -$11.4K 0.02% 164
2026
Q1 		$99.7K Buy
+12,998
New +$89K 0.03% 153

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hartford Financial Management's IBRX Position: Q2 2026 in Review

Hartford Financial Management reduced its ImmunityBio (IBRX) stake by 12% in Q2 2026, selling an estimated $11.4K and leaving 11,498 shares worth $101K. The position accounts for 0.02% of the portfolio, ranked #164.

Hartford Financial Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Hartford Financial Management held 11,498 shares of ImmunityBio worth $101K as of Q2 2026.
  • Hartford Financial Management sold 1,500 ImmunityBio shares in Q2 2026, an estimated $11.4K.
  • ImmunityBio made up 0.02% of Hartford Financial Management's portfolio in Q2 2026, its #164 holding.
  • Hartford Financial Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Hartford Financial Management's 13F filing for Q2 2026, filed 24 Jul 2026.